Global Economics, International Advancements and Industry Reports Findings Impacting
Sector Growth Hallmarked Day Two of 2012 BIO Convention
Day Three Convention Highlights include PDUFA Implications, Public and Industry Leaders Opinion Survey Results and Sector R&D Advancements
BOSTON – (June 20, 2012) –The world’s largest biotechnology event, 2012 BIO International Convention, showcased the global financial and business developments that are shaping the biotechnology sector during the Convention’s second day. Hosted by the Biotechnology Industry Organization at the Boston Convention and Exhibition Center, this year’s event is expected to attract more than 15,500 attendees from 48 states and 65 countries.
Highlights from Day Two:
· We are BIO
BIO President and CEO, Jim Greenwood, discussed some of the most recent biotech medical breakthroughs, the researchers who developed them and the patients who have benefitted from the new medicines.
· Super Session: Ernst and Young Beyond Borders
The fanfare surrounding Ernst & Young’s 26th annual report on the state of the biotech industry, Beyond Borders, was buoyed by positive trends outlined in the report that show despite the overall lingering uneasiness in the economy, biotech is continuing its growth momentum.
· Prior User Rights and Trade Secrets
The new prior user rights defense which came into effect with enactment of the America Invents Act (AIA) was very differently viewed by the small biotech company perspective as represented by Mary Ann Dillahunty (Oncolytics Biotech, Inc), and the large company perspective as represented by Brian Barnett with Eli Lilly.
· Recent Developments in Patentability: Prometheus and Myriad
The unanimous decision by the Supreme Court overturning a decision upholding the Prometheus patents by the Court of Appeals for the Federal Circuit raises more question than it answers. It will be quite a while before the full implications of the decision is understood, and know whether Congress will be asked to step in to clarify a very murky situation that will continue to hang over the industry.
· An Insider’s View of the BioGENEius Challenge
Each year America’s top high school science students participate in the International BioGENEius Challenge, a competition recognizing original research in biotechnology. Nathan Kondamuri, a junior from Munster High School in Dyer, Ind. won with his project titled, “A Novel Porphyrin Based Solar Cell Combining Coordinated Metal Ion Substitution and Self-Assembly to Broaden the Absorption Spectrum to Efficiently Create Sustainable.”
Day Three Session Highlights Include:
· Biotech and Big Pharma – What’s Next?
A panel of top industry executives will discuss where biotech will be in the next 10 years and how the pharmaceutical industry landscape is changing.
· Super Session: After the Honeymoon—Integrating the R&D Growth Engine
Acquisitions are driven largely by lead assets with promise, yet often come with a deep earlier stage R&D engine. At this session, Campbell Alliance and BIO will present updated findings from two forward-looking measures of deal-making in the industry—the Campbell Alliance Dealmakers' Intentions Survey and the BIO One-on-One Partnering Forecast.
· Super Session: Pre-Competitive Collaboration: Innovation of the Future?
Precompetitive collaboration is a growing driver for innovation and increased productivity in biotechnology. This session will explore the benefits and challenges of pre-competitive collaborations to advance research and development of novel medicines.
· Super Session:PDUFA V: Impact on Innovation, Patients and Modern Medicines
Industry leaders will discuss the reauthorization of the Prescription Drug User Fee Act (PDUFA V) and efforts to modernize the FDA regulatory environment, as well as the implications for patients, providers and the industry.
Follow the 2012 Convention @BIO2012, and join the conversation @IAmBIOtech.
Media registration is open June 20 from 8:00am – 5:00pm at the Boston Convention and Exhibition Center. The Convention program features more than 125 breakout sessions across 14 tracks. More than 70 percent of attendees are senior-level leaders from industry, academia and government.
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/ for the most up-to-date program and speaker information.
The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to
gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit2012 BIO International Convention.
Upcoming BIO Events
BIO India International Conference
September 12 – 13, 2012
Livestock Biotech Summit
September 19 – 21, 2012
Kansas City, MO
BIO Investor Forum
October 9-10, 2012
San Francisco, CA
The BIO Convention in China
October 24 – 25, 2012
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, a multiblog platform and monthly newsletter that aims to create an online biotech community where the the industry can connect to discuss the latest news. Subscribe to BIOtechNOW.
For more information:
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech